选择性免除浸润性乳腺癌手术:一项非随机临床试验
这项单臂前瞻性2期非随机临床试验在美国7个中心纳入50例40岁以上、新辅助全身治疗后影像学残留乳腺病灶小于2厘米的ERBB2阳性或三阴性浸润性乳腺癌患者,经影像引导真空辅助活检筛选后部分患者仅接受全乳放疗而不行乳腺手术。中位随访55.4个月,未行乳腺手术患者的同侧乳腺肿瘤复发率为0%,无病生存率和总生存率均为100%。作者认为在新辅助全身治疗后经选择的患者中免除乳腺手术可能可行,但需更多验证性研究。
要点
- 新辅助全身治疗后经影像引导真空辅助活检确认乳腺病理完全缓解的患者可仅接受全乳放疗而不行乳腺手术。
- 中位随访55.4个月,未行乳腺手术患者的同侧乳腺肿瘤复发率为0%,无病生存率和总生存率均为100%。
- 作者认为该方案可能可行,但需更多验证性研究后才能改变外科实践。
核心结论
- 这项报告预设5年结果的非随机临床试验提示,在新辅助全身治疗后经选择的患者中免除乳腺手术可能可行,未见复发。
- 作者指出,在这一新方法改变外科实践之前,需要更多验证性研究。
研究设计与样本
- 单臂、前瞻性、2期非随机临床试验,在美国7个医疗中心开展。
- 纳入40岁及以上、cT1-2N0-1M0、ERBB2阳性(原HER2阳性)或三阴性浸润性乳腺癌、新辅助全身治疗后影像学残留乳腺病灶小于2厘米的女性。
- 入组时间为2017年3月6日至2021年11月9日,数据分析时间为2024年10月至12月。
- 干预为在新辅助全身治疗后对瘤床行影像引导真空辅助活检(9G,至少12条芯)。
- 诊断时临床淋巴结阴性且新辅助全身治疗后真空辅助活检无乳腺残留癌的患者接受全乳放疗加瘤床推量,不行乳腺或腋窝手术。
主要发现
- 共50例患者入组并接受新辅助全身治疗后真空辅助活检,中位(IQR)年龄62(55-77)岁。
- 29例(58%)为ERBB2阳性浸润性乳腺癌,21例(42%)为三阴性浸润性乳腺癌。
- 真空辅助活检发现乳腺病理完全缓解31例(62%;95% CI,47.2%-75.34%)。
- 初始有淋巴结转移且真空辅助活检示乳腺病理完全缓解并接受靶向腋窝清扫的全部8例患者均发现腋窝病理完全缓解。
- 中位随访55.4(IQR,44.0-63.5)个月,未行乳腺手术患者的同侧乳腺肿瘤复发率为0%,无病生存率和总生存率均为100%。
关键数值与推荐
- 诊断时临床淋巴结阴性且新辅助全身治疗后真空辅助活检无乳腺残留癌者行全乳放疗加推量,不行乳腺或腋窝手术。
- 初始有记录的淋巴结病变且真空辅助活检示乳腺病理完全缓解者行靶向腋窝清扫。
- 真空辅助活检时仍有残留癌者行标准乳腺和腋窝手术。
- 患者每6个月接受体格检查和乳腺X线摄影监测。
临床怎么用
- 原文未据此给出推荐。
- 作者认为在新辅助全身治疗后经选择的患者中免除乳腺手术可能可行,未见复发,但需更多验证性研究后才能改变外科实践。
局限性
- 作者指出在这一新方法改变外科实践之前需要更多验证性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neoadjuvant systemic therapy (NST) has been associated with pathologic complete response (pCR) in up to 60% of breast cancers (BCs). The findings of this trial question the necessity of surgery. OBJECTIVE: To report preplanned 5-year efficacy outcomes evaluating radiotherapy alone without breast surgery in patients selected with image-guided vacuum assisted biopsy (VAB). DESIGN, SETTING, AND PARTICIPANTS: This single-arm, prospective, phase 2 nonrandomized clinical trial was conducted at 7 US medical centers and included women 40 years or older with cT1-2N0-1M0 ERBB2-positive (formerly HER2-positive) or triple-negative invasive BC who showed residual breast lesions after NST of less than 2 cm on imaging. Enrollment was from March 6, 2017, to November 9, 2021. Data analysis was from October to December 2024. INTERVENTION: Image-guided VAB of the tumor bed (9G with a minimum of 12 cores) was performed after standard NST. Patients with clinically node-negative disease at diagnosis and no residual cancer in the breast on post-NST VAB underwent whole-breast radiotherapy with a boost without breast or axillary surgery. Patients with initial documented nodal disease and a breast pCR on VAB underwent targeted axillary dissection, while those with residual cancer when undergoing VAB had standard breast and axillary surgery. Patients were monitored with physical examinations and mammography every 6 months. MAIN OUTCOME MEASURES: The primary outcome was ipsilateral breast tumor recurrence. RESULTS: Fifty patients (median [IQR] age, 62 [55-77] years) were enrolled and underwent post-NST VAB. Twenty-nine (58%) and 21 (42%) patients had ERBB2-positive and triple-negative invasive BC, respectively. Breast pCR on VAB was identified in 31 patients (62%; 95% CI, 47.2%-75.34%), and axillary pCR was identified among all 8 patients with initial nodal metastases and breast pCR on VAB who underwent targeted axillary dissection. At a median follow-up of 55.4 (IQR, 44.0-63.5) months, the ipsilateral breast tumor recurrence rate was 0%, and disease-free and overall survival rates were 100% for patients without breast surgery. CONCLUSIONS AND RELEVANCE: The results of this nonrandomized clinical trial that reported preplanned 5-year outcomes suggest that omission of breast surgery in select patients after NST may be feasible, with no recurrences seen. More confirmatory studies are necessary before this new approach alters surgical practice. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02945579.
引用
- Kuerer HM, Valero V, Smith BD, et al. Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial. JAMA Oncol. 2025. PMID: 40152443. doi:10.1001/jamaoncol.2025.0207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。